Canaccord analyst Austin Moeller lowered the firm’s price target on Bioceres (BIOX) to $6.50 from $7 and keeps a Buy rating on the shares. The firm noted management announced its intent to pivot away from Bioceres’ seed business to focus on trait development and leverage key partnerships to expand its footprint internationally.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX: